Krystal Biotech appoints Jing Marantz as CBO, adds Rand Sutherland to board

Krystal Biotech, Inc.

Jing Marantz resigns from board effective Jan 18, 2022, to become Chief Business Officer.
E. Rand Sutherland appointed to board same day; no committee assignments initially.
Marantz previously SVP at Acceleron, Alnylam, Alexion; Sutherland was president of Translate Bio.
Marantz's resignation not due to any disagreement with Krystal.
Both appointments effective January 18, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

E. Rand Sutherland

Director

KRYS · Krystal Biotech, Inc.

Effective: 2022-01-18
Filed: January 18, 2022, 6:59 PM ET

On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.

Appointed

Jing Marantz

Chief Business Officer

KRYS · Krystal Biotech, Inc.

Effective: 2022-01-18
Filed: January 18, 2022, 6:59 PM ET

Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.

Departed

Jing Marantz

Director

KRYS · Krystal Biotech, Inc.

Effective: 2022-01-18
Successor: E. Rand Sutherland
Filed: January 18, 2022, 6:59 PM ET

On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

E. Rand Sutherland was appointed as Director at Krystal Biotech, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Jing Marantz was appointed as Chief Business Officer at Krystal Biotech, Inc..

Action: commenced
Role: Chief Business Officer

Exact text from the filing

Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jing Marantz resigned as Director at Krystal Biotech, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).

View on SEC.gov

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-011224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.